Background: As the number of medications increases, the appropriateness of polypharmacy may become questionable due to the heightened risk of medication-related harm.
Objectives: (1) To investigate the relationship between the number of current medications used by older adults and three indicators of potentially inappropriate polypharmacy: (a) the mean number of potentially inappropriate medications (PIMs), (b) the average count of drug-drug interactions, and (c) the anticholinergic burden; (2) To characterize the population-based burden of potentially inappropriate polypharmacy by calculating the proportion of individuals with these indicators.
Design: We conducted a population-based observational study using the Quebec Integrated Chronic Disease Surveillance System.
Methods: We included all individuals over 65 years insured by the public drug plan on April 1st, 2022. For each individual, we calculated the number of current medications and the number of (a) PIMs (Beers 2019), (b) drug-drug interactions (Beers 2019), and (c) anticholinergic burden (Anticholinergic Cognitive Burden (ACB) scale). The association between the number of medications and these indicators was quantified using linear regression. Prevalence with 99% confidence intervals (CIs) was calculated.
Results: A total of 1,437,558 individuals (mean age: 75; 55% female) were included, taking an average of 4.9 medications (±4.1). For each additional medication, the mean number of PIMs, drug-drug interactions, and anticholinergic burden increased by 0.11, 0.04, and 0.17, respectively (-trend <0.0001). Nearly half the population (45.5%; 99% CI: 45.5-45.5) had a regimen containing ⩾1 PIMs, ⩾1 drug-drug interaction, or an ACB ⩾3.
Conclusion: The strong association between the increasing number of medications and reduced polypharmacy quality underscores the importance of medication count beyond therapeutic indications. With widespread medication use, many older adults face quality issues.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11683794 | PMC |
http://dx.doi.org/10.1177/20420986241309882 | DOI Listing |
Neurochem Res
January 2025
College of Pharmacy, Guangxi Medical University, Guangxi Zhuang Autonomous Region, Nanning, 530021, China.
To study the neuronal protective effect and its potential mechanism of C16 against gp120-induced cognitive impairment in vitro and in vivo. The NORT method was used to evaluate the short-term memory abilities of rats, the morphological changes in hippocampus were observed by Nissl staining. Cell viability and damage degree were detected by MTT and LDH.
View Article and Find Full Text PDFWorld J Pediatr
January 2025
Binjiang Institute of Zhejiang University, Hangzhou, 310053, China.
Background: Digital technologies play an important role in improving the quality of healthcare services, however, many healthcare workers and students do not recognize this and have low levels of digital competencies and skills. Therefore, this paper aims to investigate digital perceptions and competencies among medical students in pediatrics and pediatric healthcare workers in China.
Methods: A questionnaire on digital competency was designed.
Inflammopharmacology
January 2025
Department of Pharmacology, Faculty of Pharmacy, The Islamia University of Bahawalpur, Punjab, 63100, Pakistan.
Clove oil obtained from Syzygium aromaticum (L.) is traditionally employed to treat inflammation associated with rheumatism, gastric disorders, and as an analgesic. Chemo-herbal combinations are known to have potent anti-inflammatory and analgesic effects, while mitigating the drug related side effects.
View Article and Find Full Text PDFInt Urol Nephrol
January 2025
Faculty of Medical Sciences, Pharmacology and Toxicology Department, University of Kragujevac, Kragujevac, Serbia.
Purposes: Intermediate-risk prostate cancer (IR PCa) is the most common risk group for localized prostate cancer. This study aimed to develop a machine learning (ML) model that utilizes biopsy predictors to estimate the probability of IR PCa and assess its performance compared to the traditional clinical model.
Methods: Between January 2017 and December 2022, patients with prostate-specific antigen (PSA) values of ≤ 20 ng/mL underwent transrectal ultrasonography-guided prostate biopsies.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!